SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

ALN-2232

ALNY·ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating1/10
Trial phase
Not stated
Time to market
unknown, no clinical or regulatory stage could be verified
Why 1/10
No dated catalyst exists for ALN-2232 in the next ~12 months, the molecule has no identifiable clinical trial, regulatory filing, PDUFA, or public disclosure in any source retrieved this session, so the impact score sits at the bottom of the scale.
Actionable Insight NEUTRAL

Do not trade ALNY on the basis of ALN-2232, there is no verifiable evidence this candidate is a disclosed clinical-stage program, and it cannot be distinguished from an early/undisclosed preclinical code or a data-entry artifact. Watch Alnylam's official pipeline disclosures (10-K/10-Q, investor day) for any first mention of ALN-2232 before assigning it any value; company-level catalysts that ARE documented (e.g., Regeneron's cemdisiran NDA submission for generalized myasthenia gravis on 2026-04-30) are unrelated to this code.

Price Chart

Loading chart...

Executive Summary

ALN-2232 could not be verified as a real, disclosed Alnylam program by any means available this session. The sponsor ticker is verified as ALNY (Alnylam Pharmaceuticals, Inc., Nasdaq, CIK 1178670), a large-cap with strong analyst coverage (mean price target $427.61 vs. ~$204 share price at 2026-07-31, per local snapshot) but a sharply beaten-down stock (-31.9% 1-month, composite quant score -59). Since no verifiable information about this specific molecule exists, the drug itself merits a neutral rating and minimal impact score until Alnylam publicly discloses it.

How It Works

Cannot be stated from evidence: no source retrieved this session describes what ALN-2232 targets or how it works. For context only: the developer, Alnylam Pharmaceuticals, is a Nasdaq-listed biopharma whose documented pipeline in SecBot's data centers on RNAi-style medicines for cardiovascular and rare diseases (e.g., zilebesiran for hypertension, patisiran for ATTR amyloidosis, cemdisiran for myasthenia gravis). None of those documented programs carries the ALN-2232 code.

Trial Status

No clinical trial records exist for ALN-2232 in the local ClinicalTrials.gov-backed dataset (searched by drug name, ticker ALNY, and free text) or in FDA/local catalyst datasets.

The Two-Sided Case

▲ Bull Case2
If ALN-2232 is a real but undisclosed early-stage Alnylam candidate, it inherits the platform and balance sheet of a proven RNAi developer: the company's Q2 2026 filings show strong product revenue growth and analyst consensus is Buy-leaning (21 Buy + 8 Strong Buy vs 9 Hold, per local analyst snapshot).
Institutional accumulation was detected in Q2 2026 (four tracked managers net-buying ~$15M, zero sellers, per local institutional-cluster report), indicating continued professional interest in the ALNY story overall.
▼ Bear Case3
Zero verifiable evidence of clinical or regulatory progress: no trial, no FDA record, no catalyst, and no press coverage of ALN-2232 was retrievable this session, it may be preclinical, inactive, or a non-existent code.
Company-level headwinds documented this session: Q2 2026 EPS of $1.84 missed consensus of $2.15, revenue of $1.291B missed $1.32B, and FY2026 TTR net revenue guidance was cut to $4.2B-$4.5B (per local earnings report and 8-K).
ALNY stock is under severe technical/quant pressure regardless of pipeline news: 1-month return -31.9%, RSI-14 of 23.5, and composite quant score of -59 (local snapshot as of 2026-07-31).

Upcoming Catalysts

  • None identifiable for ALN-2232 itself (no trial, filing, or readout date exists in any retrieved source).
  • Company-level (unrelated to this drug): FDA decision path on Regeneron-submitted cemdisiran NDA for generalized myasthenia gravis (submitted 2026-04-30 per local catalyst record); quarterly earnings; any future Alnylam pipeline update that might disclose ALN-2232.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov